Inotiv (NASDAQ:NOTV) Posts Earnings Results, Misses Estimates By $0.10 EPS

Inotiv (NASDAQ:NOTV) announced its earnings results on Wednesday. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.10), Zacks reports. Inotiv had a negative net margin of 22.10% and a negative return on equity of 15.86%.

Inotiv Price Performance

Shares of NASDAQ:NOTV traded down $0.31 during midday trading on Wednesday, reaching $4.18. 813,127 shares of the company’s stock traded hands, compared to its average volume of 622,475. Inotiv has a 1 year low of $1.23 and a 1 year high of $11.42. The company has a market cap of $108.72 million, a P/E ratio of -1.00 and a beta of 3.58. The company has a debt-to-equity ratio of 2.29, a quick ratio of 1.22 and a current ratio of 1.37. The company has a fifty day simple moving average of $4.41 and a two-hundred day simple moving average of $2.79.

Insider Activity

In related news, CEO Robert Jr. Leasure sold 22,700 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $4.15, for a total value of $94,205.00. Following the completion of the transaction, the chief executive officer now directly owns 1,030,209 shares of the company’s stock, valued at approximately $4,275,367.35. This represents a 2.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael J. Harrington acquired 10,000 shares of Inotiv stock in a transaction that occurred on Friday, December 6th. The stock was purchased at an average cost of $3.98 per share, with a total value of $39,800.00. Following the completion of the purchase, the director now owns 37,500 shares in the company, valued at $149,250. The trade was a 36.36 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 71,029 shares of company stock worth $314,248 and have sold 26,872 shares worth $112,854. Insiders own 7.80% of the company’s stock.

Inotiv Company Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.